{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:13:46Z","timestamp":1786990426418,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ijcard.2018.05.087","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:51:55Z","timestamp":1527313915000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe"],"prefix":"10.1016","volume":"270","author":[{"given":"Tracey G.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blazing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O'Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7675","authenticated-orcid":false,"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.05.087_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/HPC.0b013e3181a84613","article-title":"Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the United States: insights from the REACH Registry","volume":"8","author":"Eagle","year":"2009","journal-title":"Crit. Pathw. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0010","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.109.852749","article-title":"Cardiovascular risk prediction in patients with stable and unstable coronary heart disease","volume":"121","author":"Morrow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0015","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0020","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.115.019861","article-title":"Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0040","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0050","first-page":"1682","article-title":"Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis","volume":"103","author":"Wong","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0055","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0060","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.atherosclerosis.2006.04.006","article-title":"Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study","volume":"191","author":"Schindhelm","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1160\/TH03-08-0504","article-title":"Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis - interrelation with traditional cardiovascular risk factors","volume":"91","author":"Schillinger","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1538-7836.2009.03584.x","article-title":"Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis","volume":"8","author":"Chu","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/emj.2010.093096","article-title":"Diagnostic performance of mean platelet volume for patients with acute coronary syndrome visiting an emergency department with acute chest pain: the Chinese scenario","volume":"28","author":"Chu","year":"2011","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0080","first-page":"260","article-title":"Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction","volume":"5","author":"Yoshihisa","year":"2017","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0085","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0090","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0095","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0100","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"Mcpherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0105","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0115","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0120","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ahj.2011.07.018","article-title":"Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome","volume":"162","author":"O'Donoghue","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cgh.2013.07.041","article-title":"Should we lower lipids in nonalcoholic fatty liver disease?","volume":"12","author":"Farrell","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hep.26604","article-title":"Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice","volume":"59","author":"Tomita","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0135","doi-asserted-by":"crossref","first-page":"33652","DOI":"10.1074\/jbc.M110.152090","article-title":"Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation","volume":"285","author":"Gerin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0140","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2337\/db12-0858","article-title":"Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism","volume":"62","author":"Musso","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0145","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.mehy.2006.05.041","article-title":"Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease","volume":"67","author":"Hughes","year":"2006","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0155","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1742-1241.2006.01023.x","article-title":"Efficacy, safety and LDL-C goal attainment of ezetimibe 10\u202fmg-simvastatin 20\u202fmg vs. placebo-simvastatin 20\u202fmg in UK-based adults with coronary heart disease and hypercholesterolaemia","volume":"60","author":"Patel","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0160","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc09-1765","article-title":"Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet","volume":"33","author":"Chan","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-511X-9-29","article-title":"NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease","volume":"9","author":"Enjoji","year":"2010","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0170","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0175","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2018.05.087_bb0180","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1756283X15621232","article-title":"Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial","volume":"9","author":"Lin","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Writing","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0190","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1478-3231.2011.02673.x","article-title":"Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease","volume":"32","author":"Franzini","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12356-w","article-title":"Association between plasma gamma-glutamyltransferase fractions and metabolic syndrome among hypertensive patients","volume":"7","author":"Franzini","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2018.05.087_bb0200","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/oby.2011.136","article-title":"Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease","volume":"20","author":"Onat","year":"2012","journal-title":"Obesity (Silver Spring)"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318306600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318306600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:38:25Z","timestamp":1759091905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318306600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":40,"alternative-id":["S0167527318306600"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.087","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}